Therapeutic area
Study for HR+/HER2– Metastatic Breast Cancer with a PIK3CA Mutation
Therapeutic area
Oncology — Breast Cancer
General profile of the patient sought
Intended for people with HR+/HER2– metastatic breast cancer and a confirmed PIK3CA mutation whose disease has progressed after treatment with a CDK4/6 inhibitor. Participants must have received fewer than two prior lines of treatment for metastatic disease and no prior chemotherapy in that setting. Eligibility also depends on previous treatments and medical history, including diabetes, which will be reviewed by the research team.
Principal investigator
Dr. Carlos Zuloaga
A clinical study evaluating a targeted therapy combined with hormonal treatment for people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer and a PIK3CA mutation whose disease has progressed after treatment with a CDK4/6 inhibitor. The study compares two doses of the targeted therapy.